Literature DB >> 9713066

VEGF localisation in diabetic retinopathy.

M Boulton1, D Foreman, G Williams, D McLeod.   

Abstract

AIM: To determine the staining pattern of vascular endothelial growth factor (VEGF) at different stages of diabetic retinopathy (including post-laser photocoagulation) and to compare staining in excised fibrovascular and fibrocellular (non-diabetic) preretinal membranes.
METHODS: Immunohistochemical localisation of VEGF, using antibodies raised against VEGF165 and VEGF121,165,189, was carried out on specimens of normal human retina (n = 15), diabetic retinas ((a) with no overt retinopathy (n = 19), (b) with intraretinal vascular abnormalities but no proliferative retinopathy (n = 6), (c) with active proliferative retinopathy (n = 6), (d) with no residual proliferative retinopathy after photocoagulation therapy (n = 15)), excised diabetic fibrovascular membranes (n = 19), and non-diabetic fibrocellular membranes (n = 7). The degree and pattern of immunostaining was recorded.
RESULTS: In general, VEGF was absent from the majority of normal retinas. VEGF staining was apparent in most diabetic tissues but the staining pattern was dependent on both the specificity of the antibody used and the category of tissue. Staining with the VEGF165 antibody was generally confined to endothelial cells adn perivascular regions while the VEGF121,165,189 antibody was also associated with extravascular components of the inner retina. Intensity of immunostaining of diabetic eyes was dependent on the severity of retinopathy being least in diabetics with no overt retinopathy and greatest in retinas with proliferative retinopathy. Interestingly, the intensity of immunostaining in diabetic retinas which had undergone laser surgery for proliferative retinopathy was reduced to basal levels. Moderate to intense immunostaining was observed in all fibrovascular and fibrocellular membranes examined.
CONCLUSIONS: This study supports a circumstantial role for VEGF in the pathogenesis of both the preclinical and proliferative stages of diabetic retinopathy.

Entities:  

Mesh:

Substances:

Year:  1998        PMID: 9713066      PMCID: PMC1722605          DOI: 10.1136/bjo.82.5.561

Source DB:  PubMed          Journal:  Br J Ophthalmol        ISSN: 0007-1161            Impact factor:   4.638


  29 in total

1.  Localisation of vascular endothelial growth factor and its receptors to cells of vascular and avascular epiretinal membranes.

Authors:  Y S Chen; S F Hackett; C L Schoenfeld; M A Vinores; S A Vinores; P A Campochiaro
Journal:  Br J Ophthalmol       Date:  1997-10       Impact factor: 4.638

2.  Altered distribution of basic fibroblast growth factor in diabetic retinopathy.

Authors:  A Hanneken; E de Juan; G A Lutty; G M Fox; S Schiffer; L M Hjelmeland
Journal:  Arch Ophthalmol       Date:  1991-07

3.  Vascular endothelial growth factor is a secreted angiogenic mitogen.

Authors:  D W Leung; G Cachianes; W J Kuang; D V Goeddel; N Ferrara
Journal:  Science       Date:  1989-12-08       Impact factor: 47.728

4.  Human vascular permeability factor. Isolation from U937 cells.

Authors:  D T Connolly; J V Olander; D Heuvelman; R Nelson; R Monsell; N Siegel; B L Haymore; R Leimgruber; J Feder
Journal:  J Biol Chem       Date:  1989-11-25       Impact factor: 5.157

Review 5.  Tumors: wounds that do not heal. Similarities between tumor stroma generation and wound healing.

Authors:  H F Dvorak
Journal:  N Engl J Med       Date:  1986-12-25       Impact factor: 91.245

6.  The vascular endothelial growth factor family: identification of a fourth molecular species and characterization of alternative splicing of RNA.

Authors:  K A Houck; N Ferrara; J Winer; G Cachianes; B Li; D W Leung
Journal:  Mol Endocrinol       Date:  1991-12

7.  Fetal liver kinase 1 is a receptor for vascular endothelial growth factor and is selectively expressed in vascular endothelium.

Authors:  T P Quinn; K G Peters; C De Vries; N Ferrara; L T Williams
Journal:  Proc Natl Acad Sci U S A       Date:  1993-08-15       Impact factor: 11.205

8.  Association of elevated IGF-I levels with increased retinopathy in late-onset diabetes.

Authors:  D G Dills; S E Moss; R Klein; B E Klein
Journal:  Diabetes       Date:  1991-12       Impact factor: 9.461

Review 9.  Vascular permeability factor (VPF, VEGF) in tumor biology.

Authors:  D R Senger; L Van de Water; L F Brown; J A Nagy; K T Yeo; T K Yeo; B Berse; R W Jackman; A M Dvorak; H F Dvorak
Journal:  Cancer Metastasis Rev       Date:  1993-09       Impact factor: 9.264

10.  The fms-like tyrosine kinase, a receptor for vascular endothelial growth factor.

Authors:  C de Vries; J A Escobedo; H Ueno; K Houck; N Ferrara; L T Williams
Journal:  Science       Date:  1992-02-21       Impact factor: 47.728

View more
  47 in total

Review 1.  Glucose, VEGF-A, and diabetic complications.

Authors:  L E Benjamin
Journal:  Am J Pathol       Date:  2001-04       Impact factor: 4.307

2.  Early trials of angiogenic factors have not targeted patients most at risk of ocular disease.

Authors:  M McKibbin; D O'Neill
Journal:  BMJ       Date:  1999-09-04

Review 3.  The absence of diabetic retinopathy in patients with retinitis pigmentosa: implications for pathophysiology and possible treatment.

Authors:  G B Arden
Journal:  Br J Ophthalmol       Date:  2001-03       Impact factor: 4.638

4.  Characterization of a mouse model of hyperglycemia and retinal neovascularization.

Authors:  Elizabeth P Rakoczy; Ireni S Ali Rahman; Nicolette Binz; Cai-Rui Li; Nermina N Vagaja; Marisa de Pinho; Chooi-May Lai
Journal:  Am J Pathol       Date:  2010-09-09       Impact factor: 4.307

5.  Proteolytic cleavage of vascular adhesion protein-1 induced by vascular endothelial growth factor in retinal capillary endothelial cells.

Authors:  Shiho Yoshida; Miyuki Murata; Kousuke Noda; Takashi Matsuda; Michiyuki Saito; Wataru Saito; Atsuhiro Kanda; Susumu Ishida
Journal:  Jpn J Ophthalmol       Date:  2018-02-01       Impact factor: 2.447

6.  Increased ocular levels of IGF-1 in transgenic mice lead to diabetes-like eye disease.

Authors:  Jesús Ruberte; Eduard Ayuso; Marc Navarro; Ana Carretero; Víctor Nacher; Virginia Haurigot; Mónica George; Cristina Llombart; Alba Casellas; Cristina Costa; Assumpció Bosch; Fatima Bosch
Journal:  J Clin Invest       Date:  2004-04       Impact factor: 14.808

7.  Dietary taurine supplementation prevents glial alterations in retina of diabetic rats.

Authors:  Kaihong Zeng; Hongxia Xu; Mantian Mi; Qianyong Zhang; Yajie Zhang; Ka Chen; Fang Chen; Jundong Zhu; Xiaoping Yu
Journal:  Neurochem Res       Date:  2008-06-18       Impact factor: 3.996

8.  Increased levels of vascular endothelial growth factor in the aqueous humor of patients with diabetic retinopathy.

Authors:  Kocabora M Selim; Durmaz Sahan; Taskapili Muhittin; Cekic Osman; Ozsutcu Mustafa
Journal:  Indian J Ophthalmol       Date:  2010 Sep-Oct       Impact factor: 1.848

9.  ERK5 Contributes to VEGF Alteration in Diabetic Retinopathy.

Authors:  Yuexiu Wu; Yufeng Zuo; Rana Chakrabarti; Biao Feng; Shali Chen; Subrata Chakrabarti
Journal:  J Ophthalmol       Date:  2010-06-30       Impact factor: 1.909

10.  Anti-human vascular endothelial growth factor (VEGF) antibody selection for immunohistochemical staining of proliferating blood vessels.

Authors:  Chris M van der Loos; Lorine B Meijer-Jorna; Marloes E C Broekmans; Hanneke P H M Ploegmakers; Peter Teeling; Onno J de Boer; Allard C van der Wal
Journal:  J Histochem Cytochem       Date:  2010-02       Impact factor: 2.479

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.